This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
ImmunoGen (IMGN) Q3 Loss Wider, Sales Beat, '22 View Up
by Zacks Equity Research
ImmunoGen (IMGN) reports a wider-than-expected loss in third-quarter 2022. Nevertheless, it beat revenue estimates. The company raises its financial guidance for 2022
Aerie Pharmaceuticals (AERI) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Aerie (AERI) delivered earnings and revenue surprises of 35.71% and 2.91%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Zoetis' (ZTS) Lags Q3 Earnings Estimates, Lowers 2022 Guidance
by Zacks Equity Research
Zoetis' (ZTS) earnings miss estimates in third-quarter 2022. Revenues, though up, also miss estimates due to the supply constraints in the international market. Zoetis lowers its financial guidance.
The Zacks Analyst Blog Highlights SilverBow Resources, Amalgamated Financial, PHX Minerals, Richardson Electronics and Aerie Pharmaceuticals
by Zacks Equity Research
SilverBow Resources, Amalgamated Financial, PHX Minerals, Richardson Electronics and Aerie Pharmaceuticals are part of The Zacks top Analyst Blog.
Talaris (TALS) Down on Patient Death From Renal Transplant Study
by Zacks Equity Research
Talaris Therapeutics (TALS) reports a patient death from its late-stage study evaluating its experimental drug, FCR001, in living donor kidney transplant patients. Stock down.
Add These 4 Top-Ranked Liquid Stocks For Healthy Gains
by Vaishali Doshi
Here are four top-ranked liquid stocks, Oxford Industries (OXM), Aerie Pharmaceuticals (AERI), Perion Network (PERI), and Pure Storage (PSTG), which investors can add to their portfolio for returns.
5 Small Hidden Gems Flying High Despite Market's Bloodbath
by Nalak Das
We have narrowed our search to five small cap stocks that have provided more than 35% returns year to date,These are: AERI, AMAL, RELL, PHX and SBOW.
Zacks Industry Outlook Highlights Jazz Pharmaceuticals, Catalyst Pharmaceuticals, Aerie Pharmaceuticals, Larimar Therapeutics and Fusion Therapeutics
by Zacks Equity Research
Jazz Pharmaceuticals, Catalyst Pharmaceuticals, Aerie Pharmaceuticals, Larimar Therapeutics and Fusion Therapeutics have been highlighted in this Industry Outlook article.
RedHill Biopharma (RDHL) Up on New Patent for COVID-19 Candidate
by Zacks Equity Research
RedHill Biopharma (RDHL) receives a new patent from the United States Patent and Trademark Office for its investigational COVID-19 candidate, opaganib, in COVID-19 patients with pneumonia. Stock up.
Corcept (CORT) Thrives on Korlym, Overdependence a Concern
by Zacks Equity Research
Corcept's (CORT) Cushing's syndrome drug Korlym is witnessing higher sales and a strong uptake since approval. However, sole dependence on Korlym for revenues remains a headwind.
5 Stocks to Bet on in an Innovation-Driven Drug Industry
by Kinjel Shah
Innovation is expected continue driving growth in the Medical-Drugs industry in 2023. JAZZ, CPRX, AERI, LRMR and FUSN may prove to be good additions to one's portfolio.
Biogen's (BIIB) FDA Filing for ALS Drug Gets 3 Months Extension
by Zacks Equity Research
The FDA extends the review period for Biogen's (BIIB) NDA for tofersen in SOD1-ALS. This extension is due to BIIB's submission of additional data, constituting a major amendment to the earlier filing.
Reata (RETA) Up After FDA Scraps AdCom Meeting for NDA Filing
by Zacks Equity Research
The FDA decides not to hold an advisory committee meeting for Reata Pharmaceuticals' (RETA) regulatory filing seeking approval for omaveloxolone in Friedreich's Ataxia.
Are Medical Stocks Lagging Aerie Pharmaceuticals (AERI) This Year?
by Zacks Equity Research
Here is how Aerie Pharmaceuticals (AERI) and Mersana Therapeutics, Inc. (MRSN) have performed compared to their sector so far this year.
Relmada (RLMD) Lead Candidate Fails Late-Stage Depression Study
by Zacks Equity Research
Relmada's (RLMD) phase III study, evaluating REL-1017 in major depressive disorder, fails to achieve statistical significance. Shares plunge 80% following the news.
Moderna (MRNA) Up After Merck Exercises Option for Cancer Jab
by Zacks Equity Research
Merck (MRK) exercises an option to jointly develop and commercialize Moderna's (MRNA) personalized cancer vaccine as part of an existing collaboration agreement between the companies.
United Therapeutics (UTHR) Initiates Tyvaso Study in IPF
by Zacks Equity Research
United Therapeutics (UTHR) initiates a second phase III study evaluating its Tyvaso inhalation solution. The study will be conducted in sites outside the United States and Canada.
Catalyst Pharmaceuticals (CPRX) Rallies 80.69% YTD: Here's Why
by Zacks Equity Research
Catalyst (CPRX) price rallies on FDA approval of the sNDA of its lead drug, Firdapse, approved to treat LEMS in patients above six years of age.
GSK's (GSK) Boostrix Gets FDA Nod for Pertussis in Newborns
by Zacks Equity Research
Following FDA approval, GSK's (GSK) Boostrix is the first vaccine in the United States specifically approved during pregnancy to prevent disease in young infants by vaccinating pregnant women.
Catalyst Pharma's (CPRX) sNDA for Firdapse Approved by the FDA
by Zacks Equity Research
Catalyst Pharmaceuticals (CPRX) announces FDA approval of its sNDA for Firdapse to include pediatric patients for treating Lambert-Eaton myasthenic syndrome.
KemPharm (KMPH) Up On Positive Data From Sleep Disorder Study
by Zacks Equity Research
KemPharm (KMPH) reports positive top line from a study evaluating serdexmethylphenidate (SDX) for cardiovascular safety to progress the development of its prodrug KP1077.
Is Aerie Pharmaceuticals (AERI) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Aerie Pharmaceuticals (AERI) and Hanger (HNGR) have performed compared to their sector so far this year.
Feneca (FENC) Gets FDA Nod for Cancer-Related Hearing Loss Drug
by Zacks Equity Research
Feneca Pharmaceuticals (FENC) receives FDA approval for Pedmark to reduce the risk of ototoxicity associated with cisplatin in pediatric patients with localized, non-metastatic solid tumors.
Aurinia's (AUPH) Oral Lupus Drug Lupkynis Gets European Approval
by Zacks Equity Research
Aurinia Pharmaceutical (AUPH) receives marketing authorization from the European Union for its orally administered CNI immunosuppressant, Lupkynis, for treating lupus nephritis.
Regulus (RGLS) Up on Top-Line Data from Kidney Disease Study
by Zacks Equity Research
Regulus Therapeutics (RGLS) reports positive top-line data from a phase I single-dose ascending study of its lead candidate RGLS8429 in autosomal dominant polycystic kidney disease.